Nuvation Bio Inc.
NYSE: NUVB0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- New York Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- David T. Hung
- Employees
- 273
- Headquarters
- New York City, United States
- IPO year
- 2020
- Market cap
- $2.2B
- Website
- https://www.nuvationbio.com
Loading NUVB…
Loading profile data…Frequently asked questions about NUVB
What does Nuvation Bio Inc. (NUVB) do?
Nuvation Bio Inc. functions as a clinical-stage biopharmaceutical enterprise committed to discovering and advancing therapeutic solutions for oncological conditions. Its foremost experimental compound, NUV-422, is a small molecule designed to inhibit cyclin-dependent kinases (CDK)2, CDK4, and CDK6. The company's development pipeline further enco...
Where does NUVB trade?
Nuvation Bio Inc. (NUVB) trades on the New York Stock Exchange.
What sector is NUVB in?
Nuvation Bio Inc. (NUVB) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Nuvation Bio Inc.?
David T. Hung is the chief executive officer of Nuvation Bio Inc. (NUVB).
Where is Nuvation Bio Inc. headquartered?
Nuvation Bio Inc. is headquartered in United States.
Does NUVB pay a dividend?
Nuvation Bio Inc. (NUVB) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did NUVB go public?
Nuvation Bio Inc. (NUVB) completed its initial public offering in 2020.